Matthew Kulke, MD, MMSc, is director of the Neuroendocrine and Carcinoid Tumor Program at Dana-Farber and a professor of Medicine at Harvard Medical School. Kulke has led numerous clinical trials and translational studies in the neuroendocrine tumor field. A
frequent author in the field, he currently serves on the gastrointestinal cancer committee for the Alliance for Clinical Trials in Oncology, and the advisory board for the European Neuroendocrine Tumor Society. He is chair of the North American Neuroendocrine Tumor Society, and also chairs the neuroendocrine tumor guidelines panel for the National Comprehensive Cancer Network.
Jennifer Chan MD, MPH, is clinical director of the Neuroendocrine and Carcinoid Tumor Program at Dana-Farber and an assistant professor of Medicine at Harvard Medical School. Chan has broad expertise in the treatment of patients with neuroendocrine tumors. In addition to her clinical practice, she has lectured widely and published numerous articles on treatment approaches for patients with pancreatic neuroendocrine and carcinoid tumors. Chan has played a leading role in the development of novel neuroendocrine tumor therapies, and has served as the principal investigator of several investigator-initiated clinical trials. She serves on the executive committee of the North American Neuroendocrine Tumor Society and on the Neuroendocrine Tumor Task Force of the National Cancer Institute.
Kimberly Perez, MD, is a member of the DF/HCC
Gastrointestinal Oncology and Cancer Genetics and Prevention disease centers.
She received her undergraduate training at Georgetown University in Washington,
DC, and received her MD from George Washington University in Washington, DC.
She completed her residency and fellowship training at Rhode Island Hospital in
2010. After completing her fellowship, she joined the medical faculty at Warren
Alpert School of Medicine at Brown University and served as a Gastrointestinal
Oncologist at the Comprehensive Cancer Center at Rhode Island Hospital. She joined
the faculty at Dana-Farber Cancer Institute in 2015 and is currently an
Assistant Professor of Medicine at Harvard Medical School and Dana-Farber
Thomas E. Clancy, MD, is a surgical oncologist specializing in pancreaticobiliary and liver surgery at Brigham and Women's Hospital and Dana-Farber Cancer Institute, and is co-director of DF/BWCC's
Pancreas and Biliary Tumor Center. He obtained his medical degree from Harvard Medical School, followed by general surgical residency and surgical oncology fellowships at Brigham and Women's Hospital. Clancy's clinical focus is the treatment of gastrointestinal malignancies, specifically pancreatic, biliary, and liver tumors. In addition, Clancy has a specific clinical and research interest in neuroendocrine tumors. A high-volume clinical surgical oncologist, Clancy has expertise in the surgical management of primary small intestinal and pancreatic neuroendocrine tumors and resection of neuroendocrine tumor liver metastases. Clancy has been a leader in the development and adoption of minimally-invasive treatment techniques, including
Robin Sommers, DNP, ANP-BC, AOCNP, joined Dana-Farber in 2002. Sommers cares for a large population of the patients we treat within the Neuroendocrine and Carcinoid Tumor Program. Her expertise has led her to present numerous discussions on neuroendocrine tumors at various conferences and meetings. Her clinical experience and vast knowledge of the treatment of neuroendocrine tumors have made her a huge contributor to our program.
Nina Grenon, DNP, AGCNP-BC, AOCN
See the complete list of
our gastrointestinal cancer specialists.